Animal Biotechnology Market Size, Share and Global Trend By Animal (Livestock , Companion), By Type of Product (Drugs, Vaccinations, Diagnostic Tests, Genetic & Reproductive Products , Others), By Application (Diagnosis of Animal Diseases, Treatment of Animal Diseases, Preventive Care of Animals, Development of Animal Pharmaceuticals), and Regional Forecast, 2024-2032

Animal biotechnology refers to the usage of engineering, science, and technology to modify and improve living organisms such as animals. Animal biotechnology can also be further explained as the part of biotechnology where molecular biotechnology techniques are utilized to engineer genetically or modify the genome of various animals to improve the suitability of them in various applications such as pharmaceutical, industrial or agricultural.

Animal biotechnology at the same instance uses several methods in order to diagnose the various diseases in animals, enablement of treatment of these diseases through several therapeutic options and also the development of animal pharmaceuticals and preventive care for animals through veterinary vaccines. The process of vaccination is a highly effective and critical tool for preventing animal diseases and for promoting animal health and welfare, safe food production and public health.

Veterinary vaccines play a crucial role in animal health protection by preventing and controlling serious epizootic diseases. Animal diseases are also a negative constraint to sustained agricultural development and food security and can disrupt the economic benefits of international trade in livestock commodities. Veterinary vaccines have major implications on human health because of the animal to human transmission of diseases such as rabies, plaque, listeriosis, and query fever. These trends are expected to positively contribute to the market’s growth.

The global animal biotechnology market is anticipated to grow owing to a number of factors such as the increasing prevalence of animal diseases, increasing incidences of zoonotic diseases and increase in pet ownership. Other factors contributing to the growth of the market include increased demand for meat and animal-based products, usage of animals in agriculture, easy accessibility and affordability of treatment, increasing awareness of animal health and welfare, increasing role of animals in development of pharmaceutical for humans and increasing animal adoption. According to Animal Cancer Foundation, there are 65 million dogs and 35 million cats in the U.S., out of which every year there are 6 million new cancer diagnoses in dogs and similarly in cats too. In a research study published in Nature, it was estimated that appendicular osteoarthritis-affected 200,000 dogs in the U.K. annually. These trends combined with the other factors are expected to positively drive the market growth.

The factors limiting the growth of the global animal biotechnology market are the high cost of animal biotechnology and its products and ethical concerns regarding animal biotechnology products.

Key Players Covered

Some of the major companies that are present in the global animal biotechnology market are Zoetis, Boehringer Ingelheim International GmbH, Bayer AG, Intervet Inc., Sanofi, Santa Cruz Biotechnology, Inc., and others.

SEGMENTATION

Among the segmentation, diagnosis of animal diseases and treatment of animal diseases in the application segment is projected to hold a considerable share of the global animal biotechnology market due to higher usage of these applications in the treatment and management of animal diseases.

Key Insights

• Regulatory scenario for key countries
• Overview of prevalence of epizootic diseases by key countries
• Recent industry developments such as partnerships, mergers, and acquisitions
• New product launches
• Recent advances in research & development in animal biotechnology

• Regional Analysis

North America dominates the global animal biotechnology market due to a number of factors such as the rising pet adoption rates, increasing prevalence of animal diseases especially zoonotic and infectious, increasing expenditure on animal health, growing pool of veterinarians, large number of research & development activities for pharmaceutical development and large number of hospitals & clinics. The Asia Pacific is the fastest emerging market due to large livestock animal pool, increasing incidences of animal disorders, increasing awareness of animal welfare and introduction of government initiatives are expected to contribute positively in the market’s growth.

Key Industry Developments

• In January 2019, Boehringer Ingelheim International GmbH announced the launch of the first veterinary vaccines produced in China. The vaccine is swine vaccine Ingelvac PRRS MLV and is produced in China Medical City in Taizhou in the Jiangsu Province.
• In February 2018, Zoetis Inc. announced the launch of its in-house veterinary diagnostic instrument for the high volume veterinary clinics and regional laboratories called the Carysta HVC
• In April 2017, Ivaoes Animal Health announced the launch of a new anesthesia product called the Rapanofal (propofol emulsion injection), the only FDA approved propofol product formulation for the canines and felines